Sublethal Auranofin Potentiates Tumor Responses to ATR Inhibition by Inducing Oxidative DNA Damage Selectively in Cancer Cells

shan zhang,Yue Zhao,Xueqi Wang,Ce Qi,Jialiang Tian,Zhihua Zou

DOI: https://doi.org/10.2139/ssrn.4381250

2023-01-01

Abstract:Inhibition of the DNA damage response (DDR) enhances therapeutic effects of DNA-damaging cancer therapies by blocking induction of DNA repair and driving cancer cells to pass through the cell cycle with unrepaired DNA lesions. However, lack of cancer selectivity limits the clinical use of DDR inhibitors in combination with DNA-damaging anticancer treatments. Here we show that inhibition of thioredoxin reductase by subtoxic concentrations of auranofin induces oxidative DNA damage selectively in cancer cells which sensitizes them to ATR inhibition. Nontoxic doses of auranofin alone elevate ROS levels in cancer but not noncancerous cells, resulting in oxidative DNA damage and activation of the ATR-Chk1 DDR pathway specifically in cancer cells. Inhibition of ATR in auranofin-treated cancer cells results in unscheduled firing of dormant replication origins, abrogation of S phase checkpoint and extensive DNA breakage, leading to replication catastrophe and potent synergistic lethality. Inhibition of ROS or the DNA glycosylase OGG1, or blocking DNA replication by aphidicolin, significantly reduces replication stress and synergistic cytotoxicity, implicating a replication stress-driven catastrophic cell death mode resulted from collision between DNA damage and dysregulated DNA replication. In vivo, auranofin and the ATR inhibitor VE822 coadministration enables complete regressions of tumor xenografts, while each drug alone has no effect. Our data suggest that cancer-specific synergistic lethality is attainable by ATR inhibition in combination with specific pro-oxidative agents. The combination exploits an oxidative stress-driven cancer vulnerability to achieve selective targeting of cancer.